NDAINTRAVENOUSPOWDER
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYTELO (imetelstat sodium) is a small-molecule telomerase inhibitor approved in June 2024 for treating myelodysplastic syndromes (MDS). It works by inhibiting telomerase activity, an enzyme that allows cancer cells to replicate indefinitely. The drug is administered intravenously as a powder formulation.
Growth13.0 years to LOE
Early commercial phase with significant revenue-building opportunity; leadership roles prioritized over field-level positions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
Started Oct 2012
80 enrolled
Primary MyelofibrosisSecondary MyelofibrosisMyeloid Malignancies
Career Relevance
RYTELO positions professionals in leadership and account management roles focused on rapid market penetration in oncology. Strong career growth opportunity driven by early-stage commercial expansion and leadership hiring in a newly launched, protected asset.
Director
Worked on RYTELO at Geron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.